Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

I-BET151 (GSK1210151A), BET Inhibitor

Related Products

I-BET151 (GSK1210151A), BET Inhibitor

$109.00
A potent and selective inhibitor of the bromodomain and extra terminal (BET) family proteins BRD2, BRD3, and BRD4.
Catalog No. Unit Price Qty
M66053-2s 2mg solid $109.00
M66053-2 10 mM in DMSO (0.482 mL) $109.00
M66053-50s 50mg solid $850.00

Details

Product Information
Molecular Weight: 415.44
Formula: C23H21N5O3
Purity: ≥98%
CAS#: 1300031-49-5
Solubility: DMSO up to 100mM
Chemical Name: 7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-(pyridin-2-yl)ethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

I-BET151 (GSK1210151A) is a novel and selective inhibitor of the bromodomain and extra terminal (BET) family proteins BRD2, BRD3, and BRD4 with IC50 of ~0.5 μM, 0.25 μM, and 0.79 μM respectively. It has profound effects on human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis. The mode of action of I-BET151 is, at least in part, due to the inhibition of transcription at key genes (BCL2, C-MYC and CDK6) through the displacement of BRD3/4, PAFc and SEC components from chromatin.  In vivo studies indicate that I-BET151 can provide survival benefit in two distinct mouse models of murine MLL–AF9 and human MLL–AF4 leukaemia.  I-BET151 is also an ApoA1 upregulator that was also found to mediate potent anti-inflammatory effects. It showed a broad anti-inflammatory profile in a LPS-challenged Balb/C mouse model.

 

How to Use:

  • In vitro:  I-BET151 was used at 10 µM final concentration in various in vitro assays.
  • In vivo: IP administration of I-BET151 at 30 mg/kg once per day was shown to provide survival benefit in two distinct mouse models of murine MLL–AF9 and human MLL–AF4 leukaemia. Oral administration of I-BET151 at 10 mg/kg once per day in mice showed efficacy in acute inflammation mouse model.

 

Reference:

  • 1.  Dawson MA, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. (2011) Nature. 478(7370):529-33. .
  • 2.  Mirguet O, et al. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. (2012) Bioorg Med Chem Lett. 22(8):2963-7.
  • 3.  Seal J, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). (2012) Bioorg Med Chem Lett. 22(8):2968-72.

 


Products are for research use only. Not for human use.

Description

Details

Product Information
Molecular Weight: 415.44
Formula: C23H21N5O3
Purity: ≥98%
CAS#: 1300031-49-5
Solubility: DMSO up to 100mM
Chemical Name: 7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-(pyridin-2-yl)ethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

I-BET151 (GSK1210151A) is a novel and selective inhibitor of the bromodomain and extra terminal (BET) family proteins BRD2, BRD3, and BRD4 with IC50 of ~0.5 μM, 0.25 μM, and 0.79 μM respectively. It has profound effects on human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis. The mode of action of I-BET151 is, at least in part, due to the inhibition of transcription at key genes (BCL2, C-MYC and CDK6) through the displacement of BRD3/4, PAFc and SEC components from chromatin.  In vivo studies indicate that I-BET151 can provide survival benefit in two distinct mouse models of murine MLL–AF9 and human MLL–AF4 leukaemia.  I-BET151 is also an ApoA1 upregulator that was also found to mediate potent anti-inflammatory effects. It showed a broad anti-inflammatory profile in a LPS-challenged Balb/C mouse model.

 

How to Use:

  • In vitro:  I-BET151 was used at 10 µM final concentration in various in vitro assays.
  • In vivo: IP administration of I-BET151 at 30 mg/kg once per day was shown to provide survival benefit in two distinct mouse models of murine MLL–AF9 and human MLL–AF4 leukaemia. Oral administration of I-BET151 at 10 mg/kg once per day in mice showed efficacy in acute inflammation mouse model.

 

Reference:

  • 1.  Dawson MA, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. (2011) Nature. 478(7370):529-33. .
  • 2.  Mirguet O, et al. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. (2012) Bioorg Med Chem Lett. 22(8):2963-7.
  • 3.  Seal J, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). (2012) Bioorg Med Chem Lett. 22(8):2968-72.

 


Products are for research use only. Not for human use.

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: